AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE tech

[News]

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

More... (http://www.news-medical.net/news/20160121/AbbVie-doses-first-subject-in-adalimumab-clinical-trial-using-Halozymes-ENHANZE-technology.aspx)